ReviewNPJ Parkinson's disease2025
Investigating plasma lipid profiles in association with Parkinson's disease risk.
Review in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Brain Sphingolipid and Phospholipid Levels Are Altered in XK Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Systemic Endotoxemia, Inflammatory Activation, and Lipid Dysregulation in Parkinson's Disease: Evidence from Circulating LPS-Related Biomarkers and Plasma Lipids.International journal of molecular sciences · 2026Article
- Association of a five-metabolite and early-symptom profile with Parkinson's disease and its clinical progression.Scientific reports · 2026Article
- Multi-Omics Analysis Reveals Distinct Lipid Remodelling and Mitochondrial Stress in SH-SY5Y Cells Modelling Parkinson's Disease.Metabolites · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Parkinson's Disease (PD) is associated with lipid metabolic disturbances, but the specific roles of lipids in its pathogenesis are unclear. This Mendelian Randomization (MR) study utilized GWAS data and IVW methods to investigate plasma lipids and PD risk. The genetic predispositions to altered levels of triacylglycerols (TAGs), diacylglycerols (DAGs), phosphatidylcholines (PCs), and phosphatidylethanolamines (PEs) are associated with an increased risk of PD, while the genetic predispositions to sphingomyelin (SM) and lysophosphatidylcholines (LPCs) are associated with a reduced risk of PD. Further research is needed to establish the biological mechanisms underlying these relationships.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.